Brean Murray Upgrades Halozyme Therapeutics (HALO) to Buy; Rethinking HALO - Thesis Works With Roche Success Alone
Tweet Send to a Friend
Brean Murray upgrades Halozyme Therapeutics (Nasdaq: HALO) from Hold to Buy. Price target $13.
Brean analyst says, "After downgrading HALO ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Brean analyst says, "After downgrading HALO ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
